Pharvaris (PHVS) Income towards Parent Company (2020 - 2026)
Pharvaris' (PHVS) quarterly Income towards Parent Company came in at -$45.8 million in Q1 2026, up 6.35% YoY from -$43.0 million in Q1 2025, and up 15.14% on a QoQ basis from -$53.9 million in Q4 2025.
Pharvaris (PHVS) Income towards Parent Company (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Income towards Parent Company data on file, last reported at -$45.8 million in Q1 2026.
- Quarterly Income towards Parent Company rose 6.35% year-over-year to -$45.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$91.4 million (up 8.54% YoY) and the FY2025 annual result came in at -$198.5 million, down 36.64% from the prior year.
- Income towards Parent Company rose to -$45.8 million in Q1 2026, from -$53.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $51.8 million in Q2 2025 to a low of -$53.9 million in Q4 2025.
- A 5-year average of -$19.8 million and a median of -$30.4 million in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company surged 174.08% — and 2023, when it tumbled 207.77%.
- Tracing PHVS's Income towards Parent Company over 5 years: stood at -$40.1 million in 2022, then rose by 12.26% to -$35.2 million in 2023, then retreated by 5.39% to -$37.1 million in 2024, then slumped by 45.4% to -$53.9 million in 2025, then climbed by 15.14% to -$45.8 million in 2026.
- The last three Income towards Parent Company figures came in at -$45.8 million (Q1 2026), -$53.9 million (Q4 2025), and -$43.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.57 Mn |
| Mar 31, 2026 | -45.78 Mn |
| Dec 31, 2025 | -53.94 Mn |
| Sep 30, 2025 | -43.43 Mn |
| Jun 30, 2025 | 51.78 Mn |
| Mar 31, 2025 | -48.88 Mn |
| Dec 31, 2024 | -37.10 Mn |
| Sep 30, 2024 | -45.92 Mn |
| Jun 30, 2024 | 31.99 Mn |
| Mar 31, 2024 | -30.40 Mn |
| Dec 31, 2023 | -35.20 Mn |
| Sep 30, 2023 | -25.69 Mn |
| Jun 30, 2023 | 23.84 Mn |
| Mar 31, 2023 | -24.32 Mn |
| Dec 31, 2022 | -40.12 Mn |
| Sep 30, 2022 | -8.35 Mn |
| Jun 30, 2022 | 13.56 Mn |
| Mar 31, 2022 | -17.98 Mn |
| Dec 31, 2021 | 34,764.73 Bn |
| Sep 30, 2021 | -10.78 Mn |